CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice.
Weber
C J
CJ
Department of Surgery, Bristol Myers-Squibb, Seattle, WA, USA.
Hagler
M K
MK
Chryssochoos
J T
JT
Kapp
J A
JA
Korbutt
G S
GS
Rajotte
R V
RV
Linsley
P S
PS
D000069594:Abatacept; D000818:Animals; D000831:Animals, Newborn; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use*; D060908:CTLA-4 Antigen; D002470:Cell Survival; D002478:Cells, Cultured; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000601:surgery*; D004339:Drug Compounding; D018796:Immunoconjugates; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D016381:Islets of Langerhans Transplantation / Q000379:methods*; D051379:Mice; D016688:Mice, Inbred NOD; D010529:Peritoneal Cavity / Q000166:cytology; D011993:Recombinant Fusion Proteins; D013552:Swine; D014183:Transplantation, Heterologous
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D007328:Insulin; D011993:Recombinant Fusion Proteins; D000069594:Abatacept